Vertex Pharmaceuticals Incorporated – Product Pipeline Review

Global Markets Direct’s, ‘Vertex Pharmaceuticals Incorporated – Product Pipeline Review – 2016’, provides an overview of the Vertex Pharmaceuticals Incorporated’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Vertex Pharmaceuticals Incorporated, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Vertex Pharmaceuticals Incorporated

The report provides overview of Vertex Pharmaceuticals Incorporated including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Vertex Pharmaceuticals Incorporated’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Vertex Pharmaceuticals Incorporated’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Vertex Pharmaceuticals Incorporated’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Vertex Pharmaceuticals Incorporated

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Vertex Pharmaceuticals Incorporated’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Vertex Pharmaceuticals Incorporated Snapshot 6

Vertex Pharmaceuticals Incorporated Overview 6

Key Information 6

Key Facts 6

Vertex Pharmaceuticals Incorporated - Research and Development Overview 7

Key Therapeutic Areas 7

Vertex Pharmaceuticals Incorporated - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Combination Treatment Modalities 12

Pipeline Products - Out-Licensed Products 13

Out-Licensed Products/Combination Treatment Modalities 14

Vertex Pharmaceuticals Incorporated - Pipeline Products Glance 15

Vertex Pharmaceuticals Incorporated - Late Stage Pipeline Products 15

Phase III Products/Combination Treatment Modalities 15

Vertex Pharmaceuticals Incorporated - Clinical Stage Pipeline Products 16

Phase II Products/Combination Treatment Modalities 16

Phase I Products/Combination Treatment Modalities 17

Vertex Pharmaceuticals Incorporated - Early Stage Pipeline Products 18

Preclinical Products/Combination Treatment Modalities 18

Discovery Products/Combination Treatment Modalities 19

Vertex Pharmaceuticals Incorporated - Unknown Stage Pipeline Products 20

Unknown Products/Combination Treatment Modalities 20

Vertex Pharmaceuticals Incorporated - Drug Profiles 21

(ivacaftor + tezacaftor) 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

telaprevir 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

VX-150 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

VX-371 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

VX-210 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

VX-970 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

VX-152 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

VX-440 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

VX-803 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

VX-984 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Small Molecule to Inhibit HSP90 alpha/beta for Huntington's Disease 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

VE-465 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

VE-821 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

VX-241 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

VXC-486 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Small Molecule to Antagonize CGRP Receptor for Migraine 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Small Molecule to Inhibit PI3K Gamma for Undisclosed Indication 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Small Molecules for Multiple Sclerosis 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

VT-12008911 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

P-1055 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Vertex Pharmaceuticals Incorporated - Pipeline Analysis 46

Vertex Pharmaceuticals Incorporated - Pipeline Products by Target 46

Vertex Pharmaceuticals Incorporated - Pipeline Products by Route of Administration 48

Vertex Pharmaceuticals Incorporated - Pipeline Products by Molecule Type 49

Vertex Pharmaceuticals Incorporated - Pipeline Products by Mechanism of Action 50

Vertex Pharmaceuticals Incorporated - Recent Pipeline Updates 52

Vertex Pharmaceuticals Incorporated - Dormant Projects 59

Vertex Pharmaceuticals Incorporated - Discontinued Pipeline Products 60

Discontinued Pipeline Product Profiles 60

ALS-2158 60

telaprevir 60

VX-759 60

VX-983 60

Vertex Pharmaceuticals Incorporated - Company Statement 61

Vertex Pharmaceuticals Incorporated - Locations And Subsidiaries 64

Head Office 64

Other Locations & Subsidiaries 64

Appendix 66

Methodology 66

Coverage 66

Secondary Research 66

Primary Research 66

Expert Panel Validation 66

Contact Us 66

Disclaimer 67

List of Tables

List of Tables

Vertex Pharmaceuticals Incorporated, Key Information 6

Vertex Pharmaceuticals Incorporated, Key Facts 6

Vertex Pharmaceuticals Incorporated – Pipeline by Indication, 2016 8

Vertex Pharmaceuticals Incorporated – Pipeline by Stage of Development, 2016 10

Vertex Pharmaceuticals Incorporated – Monotherapy Products in Pipeline, 2016 11

Vertex Pharmaceuticals Incorporated – Combination Treatment Modalities in Pipeline, 2016 12

Vertex Pharmaceuticals Incorporated – Out-Licensed Products in Pipeline, 2016 13

Vertex Pharmaceuticals Incorporated – Out-Licensed Products/ Combination Treatment Modalities, 2016 14

Vertex Pharmaceuticals Incorporated – Phase III, 2016 15

Vertex Pharmaceuticals Incorporated – Phase II, 2016 16

Vertex Pharmaceuticals Incorporated – Phase I, 2016 17

Vertex Pharmaceuticals Incorporated – Preclinical, 2016 18

Vertex Pharmaceuticals Incorporated – Discovery, 2016 19

Vertex Pharmaceuticals Incorporated – Unknown, 2016 20

Vertex Pharmaceuticals Incorporated – Pipeline by Target, 2016 46

Vertex Pharmaceuticals Incorporated – Pipeline by Route of Administration, 2016 48

Vertex Pharmaceuticals Incorporated – Pipeline by Molecule Type, 2016 49

Vertex Pharmaceuticals Incorporated – Pipeline Products by Mechanism of Action, 2016 50

Vertex Pharmaceuticals Incorporated – Recent Pipeline Updates, 2016 52

Vertex Pharmaceuticals Incorporated – Dormant Developmental Projects,2016 59

Vertex Pharmaceuticals Incorporated – Discontinued Pipeline Products, 2016 60

Vertex Pharmaceuticals Incorporated, Other Locations 64

Vertex Pharmaceuticals Incorporated, Subsidiaries 64

List of Figures

List of Figures

Vertex Pharmaceuticals Incorporated – Pipeline by Top 10 Indication, 2016 8

Vertex Pharmaceuticals Incorporated – Pipeline by Stage of Development, 2016 10

Vertex Pharmaceuticals Incorporated – Monotherapy Products in Pipeline, 2016 11

Vertex Pharmaceuticals Incorporated – Out-Licensed Products in Pipeline, 2016 13

Vertex Pharmaceuticals Incorporated – Pipeline by Top 10 Target, 2016 46

Vertex Pharmaceuticals Incorporated – Pipeline by Top 10 Route of Administration, 2016 48

Vertex Pharmaceuticals Incorporated – Pipeline by Molecule Type, 2016 49

Vertex Pharmaceuticals Incorporated – Pipeline Products by Top 10 Mechanism of Action, 2016 50

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports